New curcumin and boswellia formulation demonstrates potent anti-inflammatory action
IFF Health (formerly known as Frutarom Health) introduces its new formulation of solubilized liquid curcumin extract in combination with Boswellia serrata. The ingredient is launched under the NovaSOL® brand. Developed by the German company Aquanova AG, the formula delivers superior bioavailability at low, easy to digest doses. The enhanced bioactivity of the two synergetic ingredients was demonstrated in an in-vivo study published last year. NovaSOLCurcumin/Boswellia will be unveiled at Vitafoods Asia in Singapore 25-26 September 2019, booth #J19.
Following the success of NovaSOL Curcumin as a functional ingredient for the supplement, food, and beverage markets, IFF Health introduces a new reinvigorated combination to take it to the next level.
Boswellic acids are derived from the gum of Boswellia serrata. The anti-inflammatory properties of these extracts has been demonstrated in a number of scientific publications and has led products based on the extracts to gain momentum amongst consumers as a natural, herbal dietary supplement product. Likewise, curcumin has a long history of use in Ayurvedic medicine for its positive effects in various inflammatory conditions, activity that is backed by multiple clinical studies. This spurred the company to unite the two classic botanicals into one micellar formula based on their shared positive effects in inflammatory conditions.
“The combination with Boswellia serrata as a synergetic ingredient significantly advances the beneficial properties of this formula,” explains Wouter Haazen, Product Manager of IFF Health. He notes that the diverse mechanisms of action of curcumin and boswellia have been found to naturally complement one another in targeting biological effects linked to inflammation.
Results of an in-vivo study led by Jürgen Meins, PhD, et al., published April, 2018, in the journal Nutrition demonstrated that liquid, micellar curcumin, in combination with boswellia, not only increased bioavailability of both compounds but also was associated with increased biological activity as compared to use of the compounds alone or to activity of a native mix of the herbs. Results showed that after exposure to NovaSOL curcumin combined with boswellia serratia, there were substantial reductions in serum levels of inflammatory cytokines, C-reactive proteins, and lipid peroxidation biomarkers.
“The NovaSOL delivery system provides significant opportunities to truly optimize curcumin and boswellia’s synergetic properties to maximum effect,” explains Mr. Haazen. “This is another innovative, science-based formula the Aquanova team created for IFF Health’s portfolio of next-generation products designed to support consumers’ quality of life.”
The liquid proprietary formula is developed with the advanced NovaSOL micellation technology for the solubilization of the two botanicals. The technology serves as a “nature-like” carrier system of minute particles for a range of substances by enabling ultrafine distribution of the herbs’ active components. The formulation is both water- and lipid-soluble, and highly stable enabling it to be readily adapted into food and beverage applications. In addition, the concentrated golden liquid can be delivered is small and easily digested dosages.
The enhanced bioavailability of NovaSOL Curcumin has already been established in a human clinical trial; there was an increase in bioavailability of up to 185-fold when compared to standard extracts — the most significant increase recorded to date. It has become one of the most demanded curcumin ingredients in Europe and currently appears in more than 50 products.